COMMUNIQUÉS West-GlobeNewswire

Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study
27/04/2026
Company to leverage strong durability and survival data in second-line and later metastatic squamous cell anal carcinoma Pivotal study expected to focus on patients in a post-standard-of-care patient population with no [...]
Backed by Goldman Sachs, Urgent Care Provider Xpress Wellness Appoints New Chief Operating Officer to Support Continued Growth
27/04/2026
New COO Joe Willey brings experience leading large-scale, people-first organizations to support expanding access to care across rural and suburban communities OKLAHOMA CITY, April 27, 2026 (GLOBE NEWSWIRE) -- Xpress [...]
Addgene Reinforces Its Expanding Role in Research with New Brand
27/04/2026
Marked by decades of scientific partnership, Addgene’s evolution from a pioneering plasmid repository to a trusted resource spanning all stages of research drives refreshed brand WATERTOWN, Mass., April 27, 2026 (GLOBE [...]
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months
27/04/2026
Submission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis Once-daily ZORYVE cream was well tolerated with a [...]
Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload
27/04/2026
Patent covers proprietary 2nd generation Thailanstatin analog payload designed for use in ADCs (antibody-drug conjugates) targeting cancer Approval strengthens Akari’s global intellectual property across all major [...]
Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform
27/04/2026
Raanana, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, [...]
Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026
27/04/2026
DURHAM, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, [...]
Hyperion DeFi Announces Participation in Upcoming Investor and Industry Conferences
27/04/2026
LAGUNA HILLS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), the first U.S. publicly listed DeFi company building on Hyperliquid, today announced that [...]
Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program
27/04/2026
Voucher application details focus on AUD as a major driver of the U.S. substance use crisis and the genetic targeting of AD04’s role in providing a treatment option for patients where existing treatments inadequately [...]
Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026
27/04/2026
CARLSBAD, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended March 31, 2026, before the market [...]
Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia
27/04/2026
Designation for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase (CP) without the T315I mutation previously treated with two or more tyrosine [...]
Vystar Plans Dividend Spin Off of RXAIR and Related Brands Following R3alm, Inc. Transaction
27/04/2026
Vystar Announces Strategic Direction for Vytex, FEC, and RXAIR BOSTON, MA, April 27, 2026 (GLOBE NEWSWIRE) -- Vystar Corporation (OTCQB: VYST) is focusing the majority of its resources on R3alm.com , which, is building [...]
Opus Genetics to Participate in Leading Medical Conferences in May 2026
27/04/2026
RESEARCH TRIANGLE PARK, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and [...]
TOMI Environmental Solutions, Inc. Sees Strong Interest In Its Solutions at INTERPHEX 2026
27/04/2026
Company Showcases SteraMist iHP Automation to Industry Giants Including Amgen, Merck, and Moderna; Finalizes Custom Engineering Contract for Proprietary Healthcare System FREDERICK, Md., April 27, 2026 (GLOBE NEWSWIRE [...]
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
27/04/2026
Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential. To date, more than 600 patients and [...]
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
27/04/2026
― Presented positive clinical data for pociredir, demonstrating robust and rapid fetal hemoglobin (HbF) induction, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive crisis (VOC) [...]
Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis
27/04/2026
ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16 Favorable safety profile consistent with the IL-23p19 class Updated Phase 1 PK/PD data continue to support the potential for once-yearly dosing, with longer-term [...]
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis
27/04/2026
Topline data is on track for anticipated readout in the summer of 2026 WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission [...]
Secura Bio Announces Journal of Clinical Oncology Publication of Final Results of Duvelisib PRIMO Phase 2 Trial in Relapsed/Refractory Peripheral T-cell Lymphoma
27/04/2026
Single agent duvelisib demonstrated clinically meaningful response rates, including a substantial proportion of complete responses, in a heavily pretreated PTCL population Responses highest in angioimmunoblastic T-cell [...]

Pages